Navigation Links
Increased EGFR levels may be an early marker of breast cancer
Date:4/20/2010

WASHINGTON, D.C. Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21.

The goal of the study led by Christopher Li, M.D., Ph.D., an associate member of the Epidemiology Program at the Fred Hutchinson Cancer Research Center, Seattle, was to discover and validate blood markers that could potentially be used for the early detection of breast cancer.

The study was conducted on 420 estrogen receptor-positive breast cancer patients whose blood was drawn within 17 months prior to their cancer diagnosis. The researchers validated promising markers in a similar, but completely independent set of 198 cases and controls from the Women's Health Initiative database.

One of the promising markers that was discovered and could be validated was EGFR.

EGFR levels were significantly elevated among cases compared to controls. Overall, those with the highest levels had a 2.9-fold increased risk of developing breast cancer compared to those with the lowest level.

When EGFR levels were evaluated among current users of estrogen plus progestin hormone therapy, a much larger ninefold increased risk of developing breast cancer was observed. As a single marker among current estrogen plus progestin users, EGFR had a specificity, the rate of true negative tests, of 90 percent and a sensitivity, the rate of true positive tests, of 31 percent as a breast cancer marker.

"While our results require confirmation and EGFR's performance is insufficient for it to be used as a single marker, this study is unique in that no prior studies have validated a single breast cancer early detection biomarker specimen to the degree we have here," said Li. "Our results suggest that there may indeed be detectable changes of proteins in blood within two years of making a clinical breast cancer diagnosis. Identification of these proteins could have a major impact on our ability to detect breast cancer early, when it is most treatable."

EGFR is part of the HER2 family, which has been shown to be quite important in breast cancer. Specifically, increased EGFR activity can increase the uncontrolled growth of cancer cells and EGFR is elevated in 20 percent to 81 percent of all human breast cancers. Several therapies targeting members of the HER2 family, including EGFR, have already been approved for cancer treatment.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. San Francisco Firefighters: Increased Risk for Bladder Cancer – Testing Underway
2. Children of combat-deployed parents show increased worries, even after parent returns
3. Sleep apnea tied to increased risk of stroke
4. Direct patient access to imaging test results could result in increased patient anxiety and physician overload
5. SDI Reports: Emergency Room Visits Covered by Medicaid Increased 6% in 2009
6. More Money, Increased Participation and Higher Nutritional Standards for School Meals
7. Increased radiation dose does not increase long-term side effects for prostate cancer patients
8. Weight-bearing exercise does not prevent increased bone turnover during weight loss
9. NACDS RxIMPACT "Hill Day" Features More Advocates Increased Focus on Medication Adherence
10. Hormone replacement therapy linked to increased lung cancer risk
11. Hormone thought to slow aging associated with increased risk of cancer death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an exciting, new, interactive publication where generations converge and explore the world from ... their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... RYE, New York (PRWEB) , ... February 23, 2017 , ... ... to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, ... the 30 clinical sites already enrolling children across the United States. , “There ...
(Date:2/22/2017)... East Setauket, New York (PRWEB) , ... February ... ... the main floor entrance and lobby of a new healthcare contact center in ... gleaming results. , One of the nation’s largest healthcare systems recently invested $51 ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... medical detox treatment to the thousands of individuals who have recently fallen victim to ... accredited hospital in Orange County, California, where they are free from the shame, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology: